AURORA, Ontario, June 19 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: HBP) today announced that Dr. Heman Chao, chief scientific officer at Helix BioPharma Corp., will be presenting a scientific poster describing L-DOS47 analytical method development findings at the 2009 American Association of Pharmaceutical Scientists ("AAPS") National Biotechnology Conference, which runs from June 21st to 24th at the Washington State Convention and Trade Center in Seattle, Washington.
The conference is a premier gathering of pharmaceutical and biopharmaceutical scientists addressing all areas of the manufacturing, non-clinical testing, clinical testing and regulatory treatment of established and emerging drug compounds.
The poster, entitled "Analytical Method Development for L-DOS47, a Novel Candidate for the Treatment of Lung Adenocarcinoma" provides a summary of the analytical methods which have been developed to characterize the concentration, identity, purity, enzymatic activity, and potency of lots of L-DOS47 drug substance and drug product. The work presented demonstrates that analytical methods have been successfully developed to support the manufacture, release and subsequent stability testing of GMP batches of L-DOS47 as Helix progresses towards initiating clinical testing with the product. Accompanying Dr. Chao for the poster presentation will be Dr. Juan Davagnino, associate director, biopharmaceutical development at KBI Biopharma; Helix's U.S.-based, third-party contract service provider responsible for assisting Helix in developing and executing the necessary quality control and stability testing programs for L-DOS47 drug substance and drug product lots.
|SOURCE Helix BioPharma Corp.|
Copyright©2009 PR Newswire.
All rights reserved